Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 17/20 | 0.49 |
| ▸ | PPARA | Q07869 | 5/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.49 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.48 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5211529 | 0.93 | PPARG (0.52) | PPARGPPARAPPARDLTB4RLTB4R2 | |
| SCHEMBL5212155 | 0.93 | PPARG (0.56) | PPARGPPARAPPARD | |
| SCHEMBL5209533 | 0.92 | PPARG (0.52) | PPARGPPARAPPARDLTB4RLTB4R2 | |
| SCHEMBL2519763 | 0.89 | PPARG (0.56) | PPARGPPARAPPARD | |
| SCHEMBL22281385 | 0.79 | PPARG (0.67) | PPARGPPARAPPARD | |
| SCHEMBL9491947 | 0.78 | PPARD (0.51) | PPARDLTB4RLTB4R2 | |
| SCHEMBL327275 | 0.77 | MTNR1A (0.51) | PPARGPPARAPPARD | |
| SCHEMBL9491377 | 0.76 | LTB4R (0.53) | PPARDLTB4RLTB4R2 | |
| SCHEMBL11535611 | 0.76 | LTB4R (0.53) | PPARDLTB4RLTB4R2 | |
| SCHEMBL6935194 | 0.76 | LTB4R (0.46) | PPARGPPARAPPARDLTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6645997-B2 | Agonists of peroxisome proliferator activated receptor (PPAR) alpha and/or gamma | MERCK & CO., INC. | 2003-11-11 | — | — | US | disclosed |
| EP-1324995-A2 | BENZOPYRANCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS | Merck & Co., Inc. (US) | 2003-07-09 | — | — | EP | disclosed |
| US-20020082292-A1 | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | MERCK SHARP & DOHME CORP. | 2002-06-27 | — | — | US | disclosed |
| WO-2002026729-A2 | BENZOPYRANCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS | MERCK & CO., INC. (US) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082292-A1 | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | PPARD, PPARA, PPARG | PPARG 3/4885PPARA 2/4885PPARD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.